These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 20155405

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.
    Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
    El-Bawab H, Al-Sugair AA, Rafay M, Hajjar W, Mahdy M, Al-Kattan K.
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
    [Abstract] [Full Text] [Related]

  • 6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Blood; 1999 Jul 15; 94(2):429-33. PubMed ID: 10397709
    [Abstract] [Full Text] [Related]

  • 7. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.
    Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, Castellucci P, Musuraca G, Dalpiaz G, Alinari L, Marchi E, Fina M, Pellegrini C, Farsad M, Cancellieri A, Busca A, Canini R, Pileri S, Baccarani M, Boaron M.
    Haematologica; 2007 Jun 15; 92(6):771-7. PubMed ID: 17550849
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    J Clin Oncol; 2001 Jan 15; 19(2):414-9. PubMed ID: 11208833
    [Abstract] [Full Text] [Related]

  • 12. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.
    Q J Nucl Med Mol Imaging; 2008 Mar 15; 52(1):9-16. PubMed ID: 18235420
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S, Capitanio S, De Carli F, Bongioanni F, De Astis E, Miglino M, Verardi MT, Buschiazzo A, Fiz F, Marini C, Pomposelli E, Sambuceti G.
    Eur J Nucl Med Mol Imaging; 2016 Feb 15; 43(2):232-239. PubMed ID: 26283504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E.
    Ann Oncol; 2005 Sep 15; 16(9):1524-9. PubMed ID: 15946979
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.